MALVERN, Pa., Oct. 24, 2011 (SEND2PRESS NEWSWIRE) — Reaction Biology Corporation (“RBC”), a leading contract research organization providing drug discovery services in epigenetics, today announced the rollout of a new product line, recombinant proteins for epigenetic research. RBC’s initial offerings will emphasize the histone methyltransferases (HMTs), including exclusive targets for which there has been no previous commercial source.
The enzymes offered for sale are active and validated for use in high-throughput screening assays. In the case of the HMTs those assays employ RBC’s proprietary HotSpot(SM) methodology, which couples economical screening with the data quality of a “gold standard” radiometric approach. HMTs are also routinely assayed by conventional scintillation counting in a plate format (TopCount).
“Our assay expertise is helping us make better enzymes, while the ability to produce new proteins in-house will help us expand the range of assays we can offer, and provide our clients with a more complete drug discovery process,” said Konrad Howitz, RBC’s Director of Epigenetics.
In addition to the HDAC, Sirtuin, HMT, DNMT and HAT assays currently offered, RBC has innovative assays for demethylases and epigenetic readers in active development.
Based in Malvern, PA, RBC has become a premier provider of drug screening and profiling services. With more than 400 kinases, RBC’s coverage of the kinome is the broadest in the industry. Using its proprietary HotSpot(SM) technology and other innovations, RBC is expanding its already substantial coverage of epigenetic regulatory enzymes. RBC has provided its services to over 200 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
For more information, visit: www.reactionbiology.com.
News Source: Reaction Biology Corporation :: This press release was issued on behalf of the news source by Send2Press® Newswire, a service of Neotrope®. View all current news at: http://Send2PressNewswire.com .
Reaction Biology Corp. ("RBC") was founded to pursue new economies in HTS and biochemical assays. RBC offers outsourced screening, profiling, and assay development, at lower cost than traditional outsourcing labs. RBC also performs NIH-funded research in technology development and early stage drug discovery. Screening partnerships with industry partners are also part of the RBC portfolio.
RBC specializes in developing new nanoliter scale assaying methods. By carefully scaling down enzyme and compound volume RBC is able to offer outsourced biochemical assays at a much more economical price than other outsource or even in-house labs.
RBC's scientists have specifically studied the effects of miniaturization on standard assays, and have selected the latest technology to maintain high levels of repeatability and low error rates. RBC utilizes a proprietary suite of techniques in its low volume well-based assays. While various low-volume technologies have been available for some time, their combination must be carefully researched in order to maximize efficiencies and minimize error rates.
Haiching Ma – Chief Technology Officer
Kurumi Horiuchi – Director of Biochemistry
Sean Deacon – Customer Service Manager
Kerri Edwards – Accounting Manager
Yuan Wang – Lab Manager
Cindy Spadaro – Administration and HR
Matt Oristano – President
Matt Oristano – Chairman
Mr. Oristano is President of Alda Inc, a private investment firm. In addition, he serves on the board of USA Mobility Inc. (Nasdaq: USMO) and its audit committee. He is also on the board of Crystalplex Corporation. From 1993 to 1999, Mr. Oristano was Chairman and CEO of People's Choice TV Corp, a public wireless TV and internet company, which he founded in 1988 and sold to Sprint in 1999. Mr. Oristano has a degree in physics from Rennselaer Polytechnic Institute.
Tom Petzinger, Jr.
Mr. Petzinger is CEO of LaunchCyte, a biotechnology development firm. Mr. Petzinger also serves as Chairman of Immunetrics Inc., Proteopure Inc., and Knopp Neurosciences. Mr. Petzinger co-founded LaunchCyte following 22 years as a reporter and editor at The Wall Street Journal, where he covered technology entrepreneurship. He is a director of the Pennsylvania Biotechnology Association and author of three best-selling books.
Mr. Kramer is a Partner of Perella Weinberg Partners. Prior to selling his firm Kramer Capital Partners to Perella Weinberg, Mr. Kramer was the head of Financial Restructuring and a member of the Management Committee at Greenhill & Co. Prior to Greenhill, Mr. Kramer was the co-head of the eastern region of Houlihan Lokey Howard & Zukin and ran the Mergers and Acquisitions and Financial Restructuring businesses. Additionally, Mr. Kramer was actively involved in the founding and development of Houlihan Lokey’s merchant banking business.
Jon Kaufman, PhD
Dr. Kaufman played a key role in the creation of Reaction Biology in his former capacity as CSO of LaunchCyte, where he originated university licensing opportunities. Dr. Kaufman is also a director of Crystalplex Corp. Dr. Kaufman has worked in bioinformatics at SmithKline Beecham and in project management at Merck. He received his doctorate in biochemistry and molecular biophysics from the University of Pennsylvania, where he worked in the Center for Technology Transfer. Dr. Kaufman received his MBA in Finance from the Wharton School.
Scott Diamond, PhD
Dr. Diamond is the scientific founder of RBC. He is the director of the Penn Center for Molecular Discovery. He received his bachelor’s degree in chemical engineering in 1986 from Cornell University and his PhD from Rice University in 1990. He holds the Arthur E. Humphrey Chair of Chemical and Biomolecular Engineering.
Haiching Ma, PhD
Dr. Ma is the Chief Technology Officer of RBC. He has played indispensable roles in developing and commercializing RBC's technologies and products. He has over 20 years biomedical research experience with record publications in assay development, drug screening, chemical microarray, enzymology, protein engineering, gene delivery, and stem cell biology. Dr. Ma is the Principal Investigator for multiple SBIR awards and an RO1 award from NIH to RBC totaling over 4.5 million dollars. Dr. Ma received his PhD in Pharmacology from the Medical School of The University of Pennsylvania and continued his postdoc training there in the Institute for Medicine and Engineering.
More News From Reaction Biology Corporation:
Press Release Copr. © Reaction Biology Corporation (or “news source”) and Send2Press® Newswire. Permission granted for reproduction by news portals, aggregators and news indexes provided original attribution to this site and news source is retained. Cannot be used for commercial purposes/advertising or keyword marketing. All other rights reserved.
This press release has had 1,199 views so far.